IceCure Medical Ltd - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ICCM Nasdaq 3840 www.icecure-medical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IceCure Medical Ltd

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America - Jan 13th, 2025 12:00 pm
The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing - Jan 8th, 2025 11:17 am
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - Jan 6th, 2025 1:30 pm
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - Jan 3rd, 2025 1:30 pm
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - Dec 16th, 2024 1:30 pm
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results - Dec 5th, 2024 1:30 pm
IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Nov 27th, 2024 10:32 am
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates - Nov 26th, 2024 2:40 pm
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - Nov 26th, 2024 1:30 pm
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office - Nov 25th, 2024 1:30 pm
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - Nov 20th, 2024 1:30 pm
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health - Nov 19th, 2024 1:30 pm
IceCure’s cryoablation system for breast cancer treatment gains FDA panel support - Nov 11th, 2024 11:35 am
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer - Nov 8th, 2024 12:00 pm
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - Oct 29th, 2024 12:30 pm
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - Oct 21st, 2024 12:30 pm
Alignment HealthCare Partners With Intermountain Health in Nevada - Oct 10th, 2024 2:10 pm
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - Oct 7th, 2024 12:15 pm
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Oct 3rd, 2024 9:17 am
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - Sep 24th, 2024 12:15 pm